Microparticles, malignancy and thrombosis

Zahra, Sharon; Anderson, Julia; Stirling, David; Ludlam, Christopher A.

doi:10.1111/j.1365-2141.2010.08452.x

Cited by 47 publications

(35 citation statements)

References 79 publications

(164 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microparticle antigen expression varies according to stimulant of release [5] and this may somewhat explain the variation in findings since different antigens were targeted in the studies. CD51 (vitronectin) is a glycoprotein which binds serine proteases including plasminogen activator inhibitor (PAI-1) and the terminal complement complex and CD105 (endoglin) is a membrane glycoprotein and acts a receptor for transforming growth factor-β (TGF-β).…”

Section: Discussionmentioning

confidence: 99%

“…Two different antigens were used to confirm microparticle cell origin since microparticles are known to express different antigens according to the stimulant of their release [5].…”

Section: Isolation and Quantification Of Platelet And Endothelial Micmentioning

confidence: 99%

“…Numerous adhesion molecules, receptors, enzymes and major histocompatibility complexes (MHC) are expressed on leucocyte, endothelial and platelet microparticles and this, in addition to their size, forms the basis for microparticle detection. Microparticles have been implicated in the pathogenesis of inflammation [4], thrombosis [4] and malignancy [5]; and have been studied in conditions of cardiovascular disease such as coronary artery disease and stroke [6], haemolytic states such as TTP [7] and sickle cell disease, inflammatory conditions including Crohn's disease in addition to pregnancy, miscarriage [8,9], pre-eclampsia and venous thrombosis [10,11].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Endothelial and platelet microparticles in patients with antiphospholipid antibodies

Breen

Sanchez

Kirkman

et al. 2015

Thrombosis Research

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…Two different antigens were used to confirm microparticle cell origin since microparticles are known to express different antigens according to the stimulant of their release [5].…”

Section: Isolation and Quantification Of Platelet And Endothelial Micmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Endothelial and platelet microparticles in patients with antiphospholipid antibodies

Breen

Sanchez

Kirkman

et al. 2015

Thrombosis Research

View full text Add to dashboard Cite

“…54 In malignancy, MPs may also originate from cancer cells. 55 In 1983, Dvorak et al first demonstrated that highly procoagulant TF-bearing MPs are shed from cultured cancer cells. 56 Other well-established sources of TF-bearing MP are monocytes and endothelial cells.…”

Section: Mps and Tfmentioning

confidence: 99%

Biomarkers for prediction of venous thromboembolism in cancer

Pabinger

Thaler

2013

Blood

216

170

View full text Add to dashboard Cite

Cancer patients are at increased risk of deep vein thrombosis and pulmonary embolism. The incidence among different groups of cancer patients varies considerably depending on clinical factors, the most important being tumor entity and stage. Biomarkers have been specifically investigated for their capacity of predicting venous thromboembolism (VTE) during the course of disease. Parameters of blood count analysis (elevated leukocyte and platelet count and decreased hemoglobin) have turned out to be useful in risk prediction. Associations between elevated levels and future VTE have been found for d-dimer, prothrombin fragment 1+2, and soluble P-selectin and also for clotting factor VIII and the thrombin generation potential. The results for tissue factor–bearing microparticles are heterogeneous: an association with occurrence of VTE in pancreatic cancer might be present, whereas in other cancer entities, such as glioblastoma, colorectal, or gastric carcinoma, this could not be confirmed. Risk assessment models were developed that include clinical and laboratory markers. In the high-risk categories, patient groups with up to a >20% VTE rate within 6 months can be identified. A further improvement in risk stratification would allow better identification of patients for primary VTE prevention using indirect or novel direct anticoagulants.

show abstract

“…81 However, the use of MPs as a predictive biomarker is hampered by the lack of standardization in testing methods. 83 …”

Section: Biologic Predictive Markersmentioning

confidence: 99%

Assessing the Risk and Prognosis of Thrombotic Complications in Cancer Patients

Kyriazi

Theodoulou

2013

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Context.—Cancer is characterized by the development of a prothrombotic state. Approximately 15% to 20% and 1.5% to 3.1% of cancer patients develop venous and arterial thrombosis, respectively, whereas 18% to 20% of idiopathic venous events are caused by an occult neoplasia. The highest risk is observed in hematologic, gastrointestinal, and lung malignancies, as well as in patients with active disease, especially in the first 3 months after cancer diagnosis. Hospitalization, surgical interventions, and implanted venous devices increase the thrombotic risk. Patients with metastatic disease, febrile neutropenia, infections, and severe comorbidities experience more frequently a thrombotic event. A contemporary prechemotherapy predictive model incorporates both clinical and biologic parameters, such as the primary cancer site, platelet count, white blood cell count, hemoglobin, use of erythropoietic agents, and body mass index. Several studies aim to clarify the prognostic value of tissue factor, P-selectin, thrombin generation, microparticles, and D-dimers. Objectives.—To summarize current views on epidemiology, risk factors, and predictive variables, discussing the future perspectives and existing limitations in clinical practice. Data Sources.—Review of published literature, including review papers, epidemiologic studies, and clinical trials, in online medical databases. Conclusions.—The thrombogenic properties of tumor cells affect the prognosis and quality of life for the cancer population. Despite the improved awareness and prompt use of thromboprophylaxis, recent studies reported increased rates of thrombotic events, whereas the annual risks for thrombosis recurrence and bleeding are 21% and 12%, respectively. The clinical use of risk factors and prognostic parameters could allow for patient risk stratification and individualization of anticoagulant treatment.

show abstract

Microparticles, malignancy and thrombosis

Cited by 47 publications

References 79 publications

Endothelial and platelet microparticles in patients with antiphospholipid antibodies

Endothelial and platelet microparticles in patients with antiphospholipid antibodies

Biomarkers for prediction of venous thromboembolism in cancer

Assessing the Risk and Prognosis of Thrombotic Complications in Cancer Patients

Contact Info

Product

Resources

About